NovoCure (NVCR) Liabilities and Shareholders Equity (2014 - 2026)

NovoCure (NVCR) has reported Liabilities and Shareholders Equity for 13 consecutive years, with $795.2 million the latest figure, recorded in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 36.17% year-over-year to $795.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.7 billion (down 24.38% YoY) and the FY2025 annual result came in at $804.3 million, down 35.18% from the prior year.
• Liabilities and Shareholders Equity grew to $795.2 million in Q2 2026 per NVCR's latest filing, from $787.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NVCR reached as high as $1.4 billion in Q3 2025 and fell as low as $787.9 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $1.2 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity rose 11.39% — and 2026, when it sank 36.91%.
• Year by year, Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then dropped by 3.82% to $1.1 billion in 2023, then grew by 8.26% to $1.2 billion in 2024, then tumbled by 35.18% to $804.3 million in 2025, then fell by 1.14% to $795.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $795.2 million, $787.9 million, and $804.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.